

- IDL – intermediate density lipoprotein
- ICHDK – ischemická choroba dolních končetin
- KDIGO – Kidney disease: Improving Global Outcomes
- LDL – low density lipoprotein
- Lp(a) – lipoprotein(a)
- MDA – malondialdehyd
- MIA syndrom – malnutrition, inflammation, atherosclerosis syndrom
- MIAC syndrom – malnutrition, inflammation, atherosclerosis, calcification syndrome
- NADPH – nikotinaadeninindinukleotidfosfát

- NPC1L1 – Niemann-Pick C1- like protein 1
- Ox-LDL – oxidované LDL
- PCSK9 – proprotein konvertázy subtilisin/kexin typu 9 (proprotein convertase subtilisin/kexin type 9)
- PD – peritoneální dialýza
- PON – paraoxonáza
- sd-LDL – small density lipoprotein
- TC – celkový cholesterol
- TxL – transplantace ledviny
- VLDL – very low density lipoprotein

LITERATURA

1. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. *Kidney Int* 2014; 85: 1303–1309.
2. Vostalová J, Galandaková A, Štrebl P, et al. Oxidační stres u pacientů s náhradou funkce ledvin hemodialýzou a peritoneální dialýzou. *Vnitř Lék* 2012; 58: 466–472.
3. Ellis RJ, Small DM, Ng KL, et al. Indoxyl Sulfate Induces Apoptosis and Hypertrophy in Human Kidney Proximal Tubular Cells. *Toxicol Pathol* 2018; 46: 449–459.
4. Atamer A, Kocyyigit Y, Ecdar SA, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. *J Nephrol* 2008; 21: 924–930.
5. Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. *Am J Med* 2001; 110: 103–110.
6. Kwiterovich jr. PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am J Cardiol* 2002; 90: 30i–47i.
7. Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. *Am J Med* 1993; 94: 350–356.
8. Kotani K, Tszuzaki K, Traniguchi N, et al. LDL particle size and reactive oxygen metabolites in dyslipidemic patients. *Int J Prev Med* 2012; 3: 160–166.
9. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 1996; 276: 875–881.
10. Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. *J Lipid Res* 1998; 39: 1263–1273.
11. Millionis HJ, Elisaf MS, Tselepis A, et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. *Am J Kidney Dis* 1999; 33: 1100–1106.
12. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. *Arteriosclerosis* 1990; 10: 672–679.
13. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. *J Am Soc Nephrol* 2000; 11: 105–115.
14. Žák A, Zeman M. Sekundární dyslipidémie. In: Svačina Š (ed.) *Poruchy metabolismu a výživy*. Praha: Galén 2010, 271–288.
15. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. *J Lipid Res* 1995; 36: 211–228.
16. Dodani S, Grice DG, Joshi S. Is HDL function as important as HDL quantity in the coronary artery disease risk assessment? *J Clin Lipidol* 2009; 3: 70–77.
17. Dantoine TF, Debord J, Charnes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. *J Am Soc Nephrol* 1998; 9: 2082–2088.
18. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. *J Am Soc Nephrol* 2012; 23: 934–947.
19. Dušejovská M, Staňková B, Vecka M, et al. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five-Year Follow-up Study. *Curr Vasc Pharmacol* 2018; 16: 298–305.
20. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. *Clin Chem* 2008; 54: 788–800.
21. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. *Curr Drug Targets* 2008; 9: 196–203.
22. Tesař V. Metabolické aspekty nemoci ledvin. In: Svačina Š (ed.) *Poruchy metabolismu a výživy*. Praha: Galén 2010, 137–150.
23. de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomized clinical trial. *Lancet Diabetes Endocrinol* 2015; 3: 181–190.
24. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. *JAMA* 2007; 297: 1344–1353.
25. Su X, Zhang L, Lv J, et al. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. *Am J Kidney Dis* 2016; 67: 881–892.
26. Kim S, Ko K, Park S, et al. Effect of Fenofibrate Medication on Renal Function. *Korean J Fam Med* 2017; 38: 192–198.
27. Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent. *Nephrol Dial Transplant* 2000; 15: 1993–1999.
28. Paul S, Mohan V. Fenofibrate can increase serum creatinine levels in renal insufficiency. *J Assoc Physicians India* 2006; 54: 337.
29. McQuade CR, Griego J, Anderson J, et al. Elevated serum creatinine levels associated with fenofibrate therapy. *Am J Health Syst Pharm* 2008; 65: 138–141.
30. Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associated with fibrate therapy. *Clin Nephrol* 2001; 55: 39–44.
31. Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. *Pharmacotherapy* 2001; 21: 1145–1149.
32. Ansquer JC, Dalton RN, Caussé E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. *Am J Kidney Dis* 2008; 51: 904–913.
33. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatinemia by increasing metabolic production of creatinine. *Nephron* 2002; 92: 536–541.
34. Zeman M, Žák A, Vecka M, et al. Treatment of hypertriglyceridemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoprotein oxidation of LDL. *Ann N Y Acad Sci* 2002; 967: 336–341.
35. Kremer AE, Mettang T. Pruritus in systemic diseases: Common and rare etiologies. *Hautarzt* 2016; 67: 606–614.
36. Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. *Kidney Int* 2018; 93: 1397–1408.
37. Bláha V, Bláha M, Lánská M, et al. LDL-aféřza v léčbě familiárních hyperlipoproteinemií. *Vnitř Lék* 2014; 60: 970–976.
38. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. *JAMA* 2007; 298: 2038–2047.
39. Dron JS, Hegele RA. Genetics and lipoprotein Disorders and Traits. *Curr. Genet. Med. Rep.* 2016; 4: 130–141.